收费全文 | 49589篇 |
免费 | 2596篇 |
国内免费 | 236篇 |
耳鼻咽喉 | 966篇 |
儿科学 | 1548篇 |
妇产科学 | 924篇 |
基础医学 | 5593篇 |
口腔科学 | 1282篇 |
临床医学 | 3455篇 |
内科学 | 13336篇 |
皮肤病学 | 1463篇 |
神经病学 | 4109篇 |
特种医学 | 1434篇 |
外科学 | 7503篇 |
综合类 | 196篇 |
一般理论 | 15篇 |
预防医学 | 3245篇 |
眼科学 | 1053篇 |
药学 | 3049篇 |
1篇 | |
中国医学 | 109篇 |
肿瘤学 | 3140篇 |
2023年 | 285篇 |
2022年 | 413篇 |
2021年 | 1206篇 |
2020年 | 609篇 |
2019年 | 1200篇 |
2018年 | 1646篇 |
2017年 | 1079篇 |
2016年 | 1072篇 |
2015年 | 1155篇 |
2014年 | 1494篇 |
2013年 | 2103篇 |
2012年 | 3483篇 |
2011年 | 3658篇 |
2010年 | 2052篇 |
2009年 | 1664篇 |
2008年 | 3179篇 |
2007年 | 3275篇 |
2006年 | 3030篇 |
2005年 | 3087篇 |
2004年 | 2825篇 |
2003年 | 2685篇 |
2002年 | 2542篇 |
2001年 | 1239篇 |
2000年 | 1504篇 |
1999年 | 1161篇 |
1998年 | 323篇 |
1997年 | 272篇 |
1996年 | 280篇 |
1995年 | 225篇 |
1994年 | 175篇 |
1993年 | 170篇 |
1992年 | 434篇 |
1991年 | 310篇 |
1990年 | 282篇 |
1989年 | 219篇 |
1988年 | 227篇 |
1987年 | 229篇 |
1986年 | 177篇 |
1985年 | 172篇 |
1984年 | 156篇 |
1983年 | 131篇 |
1982年 | 87篇 |
1981年 | 90篇 |
1980年 | 75篇 |
1979年 | 84篇 |
1978年 | 60篇 |
1977年 | 45篇 |
1976年 | 52篇 |
1974年 | 42篇 |
1973年 | 42篇 |
![点击此处可从《Journal of evaluation in clinical practice》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Areas covered: Analysis included 31 RCTs published between 2010 and 2018. Retrieved trials included 2675 and 2308 patients in TTh and placebo groups, respectively. The analysis documented that TTh was not associated with an increased CV mortality or morbidity either when overall or major adverse CV events were considered.
Expert commentary: Despite present evidence it is important to recognize that the duration of the available trials is short (lower that 3 years) limiting final conclusions on this topic. In particular, the available information on possible long-term effects of TTh on CV risk is limited. Long-term safety studies are advisable to better clarify these points. 相似文献
Areas covered: The major obstacles to lead extractions are represented by the body’s response to the foreign implanted material and by the following development of fibrotic reaction between the lead and the vascular system. Several clinical factors and device features are associated with major complications and worse outcomes. Although different multiparametric scores predicting the safety and the efficacy of TLE procedures were reported, none of these scores were prospective evaluated.
Expert commentary: A correct risk stratification is needed in order to refer complex patients to centers with proven experience and avoid futile procedures. Furthermore, the identification of high-risk patients allows to perform the extraction procedure in the operating room instead of electrophysiology lab. Albeit some risk scores able to predict adverse event in cardiac lead extraction were described, there are still several limitations to their use and reproducibility. 相似文献
Essentials
- Emerging evidence shows that patients with liver disease are not protected from thrombotic events.
- We assessed the risk of venous thromboembolism (VTE) in patients with liver disease.
- The presence of VTE resulted in an increase in mortality for patients with liver disease.
- Hospitalized patients with moderate‐severe liver disease had low risk of VTE during admission.
Summary
Background and Aims
Patients with liver disease were traditionally believed to be protected against development of blood clots, but some studies have shown a potential increased risk of venous thrombotic complications. We assessed the risk of venous thromboembolism (VTE) in patients with liver disease.Methods
Data in discharge reports of patients with liver disease and control patients without liver disease were analyzed from the national inpatient sample. Incidence of VTE was compared in patients with mild, moderate‐severe or no liver disease, and the impact on in‐hospital mortality and length of stay was calculated.Results
The overall incidence of VTE for patients with no liver disease, mild liver disease and moderate‐severe liver disease was 2.7, 2.4 and 0.9 per 100 patient discharges, respectively. In the presence of VTE, in‐hospital mortality was 10.8%, 5.8%, and 21.7% for the no liver disease, mild disease and moderate‐severe liver disease, respectively. The presence of VTE resulted in an increase in mortality for patients with no liver disease (OR, 1.16; 95% CI, 1.14–1.18) and moderate‐severe liver disease (OR, 1.63; CI 95%, 1.42–1.88).Conclusions
Patients with moderate‐severe liver disease have a lower risk of VTE than those without liver disease. Development of thrombosis during admission increased the risk of in‐hospital mortality.![点击此处可从《Pacing and clinical electrophysiology : PACE》网站下载免费的PDF全文](/ch/ext_images/free.gif)